NCT01513083 (Clinical Trial/ Ado-Trastuzumab Emtansine)

Study Title
A Study of Trastuzumab Emtansine in Patients With HER2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic Function (NCT01513083)

Trial Description
This open-label, parallel group study will evaluate the pharmacokinetics and safety of ado-trastuzumab emtansine (T-DM1, Kadcyla®; Genentech, Inc.) in patients with HER2-positive metastatic breast cancer and normal or reduced hepatic function. Patients will receive trastuzumab emtansine intravenously on Day 1 of each 3-week cycle. Anticipated time on study treatment is until disease progression or unacceptable toxicity occurs.

This trial is sponsored by F. Hoffmann-La Roche. [1]

Study Data

  • Condition: Breast Cancer
  • Interventions:
    • Drugs used in this trial
  • Phase: I
  • Enrollment: 28
  • Start: February 2012
  • Completion: September 2014
  • Last verified: July 2015

Study Schematic

(Coming soon)

Click here to Return to Drug map


Last Editorial review: July 31, 2015
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.

Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.